May 30 |
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
|
May 29 |
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
|
May 14 |
TScan Therapeutics First Quarter 2024 Earnings: Misses Expectations
|
May 13 |
TScan Therapeutics GAAP EPS of -$0.32, revenue of $0.56M
|
May 13 |
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
|
May 13 |
Key Takeaways From TScan Therapeutics Analyst Ratings
|
May 13 |
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
May 9 |
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
|
May 2 |
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
May 1 |
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|